NR1H4 and Cirrhosis: Randomized trials of farnesoid X receptor agonists in cirrhosis, including trials for prevention of variceal bleeding, are ongoing, although safety concerns such as dyslipidemia and pruritus persist (Fiorucci et al., 2025).